GSK plc ADRhedged EBIT

The latest EBIT for GSKH is $45M as of September 2016. That compares with $180M in the prior-year period — down 75.6% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside GSK plc ADRhedged's historical trend and sector peers before judging valuation or financial health.

Over the past year, GSKH's EBIT moved from $180M to $45M — a 75.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GSK plc ADRhedged's operating scale or balance-sheet position.

Against its sector companies, GSKH currently prints $45M for EBIT, while the sector average sits near $2.5T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at GSK plc ADRhedged's growth, margins, and balance sheet.

A EBIT figure of $45M for GSKH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.

After noting GSKH's EBIT ($45M), review year-over-year change from $180M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.